A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of RZ-629 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Subjects
Latest Information Update: 25 Feb 2025
At a glance
- Drugs RZ 629 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Rezubio Pharmaceuticals
- 25 Feb 2025 New trial record